About Innocoll
Innocoll is a Healthcare company based in Philadelphia (United States) founded in 1985, and was acquired by Gurnet Point Capital in April 2017. Collagen-matrix systems for controlled drug delivery are developed in pharmaceuticals. Innocoll has raised $52.85 million across 15 funding rounds from investors including Morgan Stanley, Oaktree Capital Management and Newsmith. The company has 1 employees. Its chief executive, as recorded, is Anthony Zook. Its Indian entity Clonefutura Live Solutions Private Limited reported revenue of ₹5.28 Cr. Its focus areas include Life Sciences, Drug Delivery and Implants.
Company details
Innocoll was founded in 1985 in Philadelphia, United States, and operates within the specialty pharmaceutical sector. Collagen-matrix technologies, including COLLAR X and COLLAFILM, are utilized for controlled drug release implants. The product XARACOLL, combining bupivacaine with a collagen matrix, has undergone phase III clinical trials for postsurgical analgesia in hernia repair patients as part of multi-modal therapy.
- Headquarters Philadelphia, United States
- Employees 1
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website innocoll.com
- Social LinkedIn X
- Acquired by Gurnet Point Capital (Apr 2017)
- Legal Name Clonefutura Live Solutions Private Limited
- Date of Incorporation 17 Feb, 2022
- Jurisdiction Mandvi, Maharashtra, India
- Indian entity revenue₹5.28 Cr
FY 2025 · +12% YoY
- Indian entity net profit₹15.6 Lakh
FY 2025 · 3% margin
- Indian entity EBITDA₹23.1 Lakh
FY 2025 · 4% margin
- Total Equity Funding$52.85M (USD)
in 15 rounds
- Latest Funding Round$125M (USD), Debt – Conventional
Jan 2022
- InvestorsMorgan Stanley
& 4 more
- Employee Count1
- Acquired byGurnet Point Capital
(Apr 2017)
Associated legal entities of Innocoll
Innocoll operates through Clonefutura Live Solutions Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Clonefutura Live Solutions Private Limited CIN U80903MH2022PTC377002 | Active | 17 Feb 2022 | Mumbai, Maharashtra | ₹5.3 Cr | 2 | View details |
Funding Insights of Innocoll
Innocoll has successfully raised a total of $52.85M across 15 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $125 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52.85M
- Total Rounds 15
- Last Round Debt – Conventional — $125M
- First Round $30M
(Dec 2007)
- Investors Count 4
Latest 10 of 15 funding rounds of Innocoll with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $125M | Debt – Conventional | – | – | |
| Jun 2014 | Series B | – | Sofinnova Investments | – | |
| Jul 2012 | $2M | Series B | – | – | – |
| Mar 2012 | $1.1M | Debt – Conventional | – | – | – |
| Jan 2012 | $1.1M | Series B | – | – | – |
| Aug 2011 | $3.25M | Debt – Conventional | – | – | – |
| Jun 2011 | $3.25M | Series B | – | – | – |
| Apr 2011 | $3.25M | Debt – Conventional | – | – | – |
| Mar 2011 | $3.25M | Series B | – | – | – |
| Dec 2010 | $5.25M | Series B | – | – | – |
5 investors in total: 5 institutional.
Investors in Innocoll
Innocoll has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Morgan Stanley, Oaktree Capital Management and Newsmith.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Real estate fund, infrastructure fund, and private equity firm focused on multiple sectors | 1995 | oaktreecapital.com | Los Angeles, United States | |
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Investment partnerships are built and principal investments are made by B-FLEXION. | gurnetpointcapital.com | |||
Wealth management, investment advisory, and financial services are provided. | 1935 | morganstanley.com | New York, United States | |
Investment banking, portfolio management, and fund services are provided. | 2003 | newsmith.com | Reading, United Kingdom |
Investor details for Innocoll
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Clonefutura Live Solutions Private Limited (Innocoll)
Clonefutura Live Solutions Private Limited is the primary company behind Innocoll. The board of Clonefutura Live Solutions Private Limited currently have 2 directors; the longest-serving is Shreyaan Sudarshan Daga, appointed in 2022. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shreyaan Sudarshan Daga DIN 09700102 | Director | 09 Aug 2022 | 4 yrs 3 mo | Clonefutura Live Solutions Private Limited |
| Vidushi Sudarshan Daga DIN 02877136 | Additional Director | 20 Dec 2024 | 1 yr 10 mo | Clonefutura Live Solutions Private Limited |
People of Innocoll
3 people are tracked at Innocoll (3 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Anthony Zook | CEO & President | Leadership |
Roni King | Sales Director, Northeast Region | Leadership |
Carmel Martin Gaynor | Director of Finance | Leadership |
Complete people profiles for Innocoll
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Innocoll
Figures of Clonefutura Live Solutions Private Limited, the primary company behind Innocoll, for FY 2025. Revenue was ₹5.28 Cr (+12% year on year). Net profit was ₹15.6 Lakh (3% margin). EBITDA was ₹23.1 Lakh (4% margin).
- ₹5.28 CrRevenue · FY 2025 · +12% YoY
- ₹15.6 LakhNet profit · 3% margin
- ₹23.1 LakhEBITDA · 4% margin
- ₹1.2 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Clonefutura Live Solutions Private Limited are on its company page.
Detailed financial statements for Innocoll
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Innocoll
5 dated milestones of Innocoll across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Innocoll is founded.
- Funding First funding round of $30.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Gurnet Point Capital.
- Funding Latest funding round, Debt – Conventional, of $125.0M.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Innocoll (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Innocoll
Complete news archive for Innocoll
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Innocoll
Innocoll was founded in 1985 and raised its 1st funding round 22 years after it was founded.
Innocoll is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Anthony Zook is the CEO of Innocoll, as recorded in our data.
Innocoll is a funded company, having raised a total of $52.85M across 15 funding rounds to date. The company's 1st funding round was a Series B of $5.25M, raised on Dec 2007.
Innocoll has 1 employees.
The primary company behind Innocoll, Clonefutura Live Solutions Private Limited, reported revenue of ₹5.28 Cr for FY 2025, up 12% year on year.
Innocoll was founded in 1985 in Philadelphia, United States, and operates within the specialty pharmaceutical sector. Collagen-matrix technologies, including COLLAR X and COLLAFILM, are utilized for controlled drug release implants. The product XARACOLL, combining bupivacaine with a collagen matrix, has undergone phase III clinical trials for postsurgical analgesia in hernia repair patients as part of multi-modal therapy.
Innocoll has 5 investors. Key investors include Morgan Stanley, Oaktree Capital Management, Newsmith, Sofinnova, and B-FLEXION.
Innocoll operates through Clonefutura Live Solutions Private Limited.
Yes. Innocoll was acquired by Gurnet Point Capital in April 2017.
The legal entities of Innocoll currently have 2 directors, including Shreyaan Sudarshan Daga, Vidushi Sudarshan Daga.